Irritable Bowel Syndrome (IBS) Therapeutics: Market Research Report

Date: August 22, 2011
Pages: 433
Price:
US$ 4,500.00
Publisher: Global Industry Analysts, Inc
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: IDE1C33F0ABEN
Leaflet:

Download PDF Leaflet

Irritable Bowel Syndrome (IBS) Therapeutics: Market Research Report
This report analyzes the worldwide markets for Irritable Bowel Syndrome (IBS) Therapeutics in US$ Million.

The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World.

Annual estimates and forecasts are provided for the period 2009 through 2017.

Also, a six-year historic analysis is provided for these markets.

The report profiles 50 companies including many key and niche players such as Abbott Laboratories, Alimentary Health Limited, Edusa Pharmaceuticals, Ironwood Pharmaceuticals, Inc., Forest Laboratories, Inc., Lexicon Pharmaceuticals, Pharmos Corporation, Salix Pharmaceuticals, Inc., Sucampo Pharmaceuticals, Inc., and Tioga Pharmaceuticals, Inc.

Market data and analytics are derived from primary and secondary research.

Company profiles are mostly extracted from URL research and reported select online sources.
1.INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study

2.INDUSTRY OVERVIEW

IrriTable Bowel Syndrome: A Primer
Market Analysis
World IBS Market to Witness Substantial Growth Despite of Anticipated Slump in the GI Therapeutics Market
New Drug Launches to Drive the Growth of Highly Underserved IBS Market in Developed Markets
Select Drugs in Late Stage Clinical Development
Linaclotide: One of the Most Promising Pipeline Drugs with Substantial Market Potential
IrriTable Bowel Syndrome Represents a Major Therapeutic Challenge
Available IBS Drugs: Treating the Symptoms, Not the Cause
A Comparison of Current and Previous Treatment for IBS
Select Drugs/Therapeutics Available for IBS Treatment by Symptom
Involvement of the Brain-Gut Axis Emphasized the Role of Serotonin in IBS
Serotonin 5-HT Receptors Led the Drug Development Pipeline
Lack of Selectivity Hampers Predominance of 5-HT Receptor Class of Drugs
List of 5-HT Class Drug Withdrawals/Trial Failures
Amitiza Led the IBS-C Market in 2008-2009, New Drug Launches Likely to Affect Sales
Safety Concerns of Available Drugs and Low Rate of Diagnosis Limit Market Growth
Growth Drivers
IBS Market is Presently Highly Fragmented, Generecized, and Under Served
Drug Development Programs Drive Market Growth in Developed Countries
Product Co-development, Commercialization, and Licensing Agreements
Other Growth Drivers
High Prevalence
Variable Diagnostic Criteria and IBS Prevalence
Growing Awareness
Multiple Treatment Approaches Make Way for Complementary Medicines
Need for Diagnostic Markers
Development of Novel Therapies

3.DISEASE OVERVIEW

Prevalence

Table 1. Prevalence of IBS in Select Countries/Regions of the World (includes corresponding Graph/Chart)

Prevalence by Gender: Higher Prevalence in Women
Symptoms of IBS
Comorbidities Associated with IBS
Classification of IBS Based on Symptoms
Diarrhea-predominant IBS or IBS-D
Constipation-predominant IBS or IBS-C
Alternating or Mixed Type IBS
List of Select Conditions that could be Misdiagnosed as IBS
Select Tests Recommended to Rule out GI Disorders Other than IBS
What Causes IrriTable Bowel Syndrome
The Function of the Colon
IBS and the Enteric Nervous System
The Brain-Gut Interaction
Direct Control
Indirect Control
Etiology of IrriTable Bowel Syndrome
Chronic Anxiety Mediated Visceral Hyperalgesia
Serotonin
5HT3 AND 5HT4 RECEPTORS
Genetic Factors
Gastrointestinal Infections
The Intestinal Bacteria
Diagnosis of IrriTable Bowel Syndrome
IBS Diagnostic Protocols
The Rome III Criteria for IBS Diagnosis
IBS Diagnosis in Children
The Manning Criteria for IBS Diagnosis

4.TREATMENT OF IRRITABLE BOWEL SYNDROME (IBS)

Current Treatment Scenario
Combination Therapies Offer Limited Efficacy and Short-Term Relief
An Overview of Select Treatment and Therapies for IrriTable Bowel Syndrome
Select Drug Classes Available for IBS Treatment
Dietary Fiber
List of Select Commercially Packaged Fibers
Bulk-forming Laxatives
Osmotic laxatives
List of Select Osmotic Laxatives
Poorly Absorbed Ions
Poorly Absorbed Sugars
Stimulant laxatives
List of Select Stimulant Laxatives by Type
Derivatives of Diphenylmethane
Derivatives of Anthraquinones
Emollients
Anti-Diarrheals
Antidepressants
Scientific Data Supports the Use of Antidepressants in IBS
Tricyclics: Preferred Class of Antidepressants for Treating IBS
Side Effects of TCAs
Antispasmodic Agents
Anticholinergic Agents
List of Select Anticholionergics
Peppermint Oil and Direct Smooth Muscle Relaxants
List of Select Direct Smooth Muscle Relaxants
Alternative Therapies
Probiotics
What are probiotics?
Role of Probiotics
Potential Use of Probiotics in IBS Management
Data from Research and Clinical Studies
Herbal Remedies
Psychotherapy
Others

5.PRODUCT APPROVALS IN THE PAST

Lotronex
Zelnorm
Amitiza
BENTYL® (dicyclomine hydrochloride)
Colpermin
Irribow (Ramosetron Hydrochloride)

6.PIPELINE ANALYSIS

Linaclotide
LX1031
XIFAXAN® (Rifaximin)
ASIMADOLINE
Drugs’ Early Stage Clinical Trials
Select IBS Drugs in Early Stages of Clinical Trials
Review of Pipeline Drugs in the Past (2006)

7.CLINICAL TRIALS

Synergy Pharmaceuticals to Conduct Phase II/III Trial of Plecanatide
Almirall and Ironwood Achieve Success in Second Phase III Trial of Linaclotide in IBS-C
Oxy-Powder Demonstrates Success in IBS Test
Ironwood and Forest Achieve Positive Results in Phase 3 Trial of Linaclotide
VSL 3 Proves Effective for Children Suffering from IBS
Salix’s Xifaxan (Rifaximin) Found Effective on Non-C IBS Symptom
Lexicon Concludes Phase II Clinical Trial of LX1031
Ocera Achieves Positive Result in Phase 2 Proof-of-Concept Trial of AST-120
Pharmos Achieves Positive Results in Phase 2b IBS Trial
Order-Made Souyaku to Commence IBS Drug Trials in the UK

8.RECENT INDUSTRY ACTIVITY

Tioga Receives Fast Track Status for Asimadoline in IBS-D
Canadian Institut Rosell Extends Partnership with Probi
Achieve Clinical Research Commences Clinical Trials for IBS
Wild Partners with Sterling Technology
AMRI Proposes New Drug For IrriTable Bowel Syndrome
Salix Obtains FDA’s Filing and Priority Review Approval for XIFAXAN550 in Non-C IBS
Soligenix Receives US Patent for Beclomethasone Dipropionate for IBS Treatment
Meda Takes Over Norgine’s Over-the-Counter Drugs
Tioga Reaches Agreement with FDA For Phase 3 Trials Of Asimadoline
Sucampo Files ‘Demand for Arbitration’ Against Takeda
Abbott Takes Over Solvay Pharmaceuticals
SK Holdings Obtains IND Approval from FDA for YKP10811
MicroDose Takes Over Epix’s Portfolio of Compounds
PPD Inks Agreement with Janssen Pharmaceutica
Warner Chilcott Takes Over P&G’s Global Branded Prescription Pharmaceutical Business
Abbott Acquires Solvay’s Pharmaceutical Business
Tioga and Ono Ink Licensing Agreement for IBS Drug Development
Lexicon Reacquires Joint Venture Rights from Symphony
Ironwood Enters into Partnership with Almirall
Pawfect Foods Takes Over Synergy Pharmaceuticals
Tioga and US FDA Agree on SPA for Phase 3 Efficacy Protocols of Asimadoline in IBS-D
Sucampo Obtains FDA Approval for AMITIZA for IBS-C in Adult Women
Apex and Dynogen Dissolve Merger Agreement
Rose Pharma and Eli Lily Ink Licensing Agreement Pertaining to Compound for IBS Treatment
Napo and Trine Terminate License Agreement for Crofelemer

9.PRODUCT INRODUCTIONS/INNOVATIONS

Cedars-Sinai Medical Center Introduces Rifaximin for IBS Patients
Lesaffre Introduces Probiotic Yeast to Treat Intestinal Discomfort
Lifeway Foods Launches BioKefir Range of Probiotic Drinks
Mayo Clinic Discovers Novel Genetic Variants in Serotonin Genes
Jarrow Formulas® to Introduce Ideal Bowel Support 299v®
Buscopan Launches Online Interactive Resource for IBS Patient
Chongqing Fortune Introduces Traditional Chinese Medicine
Alimentary Health to Introduce New Probiotic Treatment
Alimentary Health to Launch IBS Treatment
Astellas Pharma Introduces Irribow for IrriTable Bowel Syndrome

10.FOCUS ON SELECT PLAYERS

Abbott Laboratories (US)
Alimentary Health Limited (Ireland)
Edusa Pharmaceuticals (US)
Ironwood Pharmaceuticals, Inc. (US)
Forest Laboratories, Inc. (US)
Lexicon Pharmaceuticals (US)
Pharmos Corporation (US)
Salix Pharmaceuticals, Inc. (US)
Sucampo Pharmaceuticals, Inc. (US)
Tioga Pharmaceuticals, Inc. (US)

11.GLOBAL MARKET PERSPECTIVE

Table 2. World Recent Past, Current & Future Analysis for IrriTable Bowel Syndrome (IBS) by Geographic Region – US, Japan, Europe, Rest of World Market Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 3. World Historic Review for IrriTable Bowel Syndrome (IBS) by Geographic Region – US, Japan, Europe, and Rest of World Market Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 4. World 15-Year Perspective for IrriTable Bowel Syndrome (IBS) by Geographic Region – Percentage Breakdown of Dollar Sales for US, Japan, Europe, and Rest of World for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

12.THE UNITED STATES

A. MARKET ANALYSIS

An Overview
Prevalence of IBS-C in the US
US Leads the Global IBS Drug Development Scenario
High Unmet Needs Characterize the IBS Market
New Drugs Releases Likely to Drive Market Growth in the Near Future
IrriTable Bowel Syndrome: Key Facts
Drugs Approved for Use in IBS Treatment
Amitiza
Zelnorm
Lotronex
Strategic Corporate Developments
Focus on Select Major Players
Abbott Laboratories (US)
Edusa Pharmaceuticals (US)
Ironwood Pharmaceuticals, Inc. (US)
Forest Laboratories, Inc. (US)
Lexicon Pharmaceuticals (US)
Pharmos Corporation (US)
Salix Pharmaceuticals, Inc. (US)
Sucampo Pharmaceuticals, Inc. (US)
Tioga Pharmaceuticals, Inc. (US)
B. Market analytics

Table 5. The US Recent Past, Current & Future Analysis for IrriTable Bowel Syndrome Market Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 6. The US Historic Review for IrriTable Bowel Syndrome Market Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

13.JAPAN

A. Market analysis
Strategic Corporate Development
Product Introductions/Innovation
B. Market analytics

Table 7. Japanese Recent Past, Current & Future Analysis for IrriTable Bowel Syndrome Market Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 8. Japanese Historic Review for IrriTable Bowel Syndrome Market Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

14.EUROPE

Market Analysis

Table 9. European Recent Past, Current & Future Analysis for IrriTable Bowel Syndrome (IBS) by Geographic Region – France, Germany, Italy, UK, Spain, Russia, and Rest of Europe Market Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 10. European Historic Review for IrriTable Bowel Syndrome (IBS) by Geographic Region – France, Germany, Italy, UK, Spain, Russia, and Rest of Europe Market Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 11. European 15-Year Perspective for RNA Interference Application by Geographic Region - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, Russia, and Rest of Europe for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

14A.FRANCE

Market Analysis

Table 12. French Recent Past, Current & Future Analysis for IrriTable Bowel Syndrome Market Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 13. French Historic Review for IrriTable Bowel Syndrome Market Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

14B.GERMANY

Market Analysis

Table 14. German Recent Past, Current & Future Analysis for IrriTable Bowel Syndrome Market Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 15. German Historic Review for IrriTable Bowel Syndrome Market Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

14C.ITALY

Market Analysis

Table 16. Italian Recent Past, Current & Future Analysis for IrriTable Bowel Syndrome Market Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 17. Italian Historic Review for IrriTable Bowel Syndrome Market Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

14D.THE UNITED KINGDOM

A. Market analysis
Product Introductions/Innovation
B. Market analytics

Table 18. The UK Recent Past, Current & Future Analysis for IrriTable Bowel Syndrome Market Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 19. The UK Historic Review for IrriTable Bowel Syndrome Market Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

14E.SPAIN

A. Market analysis
Strategic Corporate Development
B. Market analytics

Table 20. Spanish Recent Past, Current & Future Analysis for IrriTable Bowel Syndrome Market Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 21. Spanish Historic Review for IrriTable Bowel Syndrome Market Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

14F.RUSSIA

Market Analysis

Table 22. Russian Recent Past, Current & Future Analysis for IrriTable Bowel Syndrome Market Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 23. Russian Historic Review for IrriTable Bowel Syndrome Market Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

14G.REST OF EUROPE

A. Market analysis
Strategic Corporate Developments
Product Introductions/Innovations
Focus on Select Key Player
Alimentary Health Limited (Ireland)
B. Market analytics

Table 24. Rest of European Recent Past, Current & Future Analysis for IrriTable Bowel Syndrome Market Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 25. Rest of European Historic Review for IrriTable Bowel Syndrome Market Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

15.REST OF WORLD

A. Market analysis
Strategic Corporate Developments
Product Introductions/Innovation
B. Market analytics

Table 26. Rest of World Recent Past, Current & Future Analysis for IrriTable Bowel Syndrome Market Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 27. Rest of World Historic Review for IrriTable Bowel Syndrome Market Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

Total Companies Profiled: 50 (including Divisions/Subsidiaries - 51)
Region/CountryPlayers
The United States
Canada
Japan
Europe
France
Germany
The United Kingdom
Italy
Spain
Rest of Europe
Asia-Pacific (Excluding Japan)
Skip to top


Irritable Bowel Syndrome Therapy Area Pipeline Report US$ 1,495.00 Sep, 2010 · 185 pages

Ask Your Question

Irritable Bowel Syndrome (IBS) Therapeutics: Market Research Report
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: